Publications by authors named "Rahif Jalloul"
Article Synopsis
- The study evaluated the effectiveness and safety of a combination treatment using liposomal cisplatin (lipoplatin) and vinorelbine in patients with metastatic breast cancer (MBC), involving 35 patients.
- The results showed a 53.1% response rate: 9.4% of patients had a complete response, and 43.8% had a partial response, with a median survival time of 22 months.
- The treatment was generally well tolerated, with significant neutropenia reported in 44% of treatment cycles, but no severe kidney or nerve damage, indicating potential for use as a first-line therapy in MBC.
Aims: The aim of this study is to evaluate the activity and toxicity of the combination docetaxel and irinotecan as first-line therapy for advanced non-small-cell lung cancer (NSCLC).
Materials & Methods: Twenty-two chemotherapy-naive patients with stage IIIB with pleural effusion or stage IV NSCLC received irinotecan 50 mg/m2 on days 1, 8, and 15, and docetaxel 50 mg/m2 on day 2, every 28 days until disease progression.
Results: Median follow-up was 10 months (range: 2-28 months).
Primary bladder tumor is a frequent urological malignancy, whereas the incidence of secondary bladder tumor from a distant organ is quite rare. Secondary bladder neoplasms represent no more than 3% of all malignant bladder tumors in surgical specimens, of which distant metastases from stomach account for about 4%. The signs of bladder neoplasm in a patient with malignancy elsewhere should alarm the clinician for a possible metastatic origin.
View Article and Find Full Text PDFBackground: We tested a sequential combination regimen using cisplatin and vinorelbine (PVn) followed by docetaxel as first-line chemotherapy in a phase II clinical trial in metastatic breast cancer (MBC).
Patients And Methods: Thirty-five patients were enrolled. Cisplatin 80 mg/m(2) was given on day 1 and vinorelbine 30 mg/m(2) on days 1 and 8 every 3 weeks for 4 cycles.
Objectives: The effectiveness of cisplatinum and vinorelbine (PVn) as a salvage regimen in patients with metastatic breast cancer was reported in previous studies. This report is a pilot study assessing the antitumor efficacy and safety of this regimen as first line therapy for advanced breast cancer patients.
Methods: Thirty-five patients were enrolled: 22 with metastatic breast carcinoma and 13 with locally advanced breast carcinoma (stage III).